Remitting seronegative symmetrical synovitis with pitting edema

Remitting seronegative symmetrical synovitis with pitting edema (or sometimes RS3PE) is a rare syndrome identified by symmetric polyarthritis, synovitis, acute pitting edema (swelling) of the back of the hands and/or feet, and a negative serum rheumatoid factor.[2] If no underlying disorder can be identified (idiopathic RS3PE), this entity has an excellent prognosis and responds well to treatment.[3]

Remitting seronegative symmetrical synovitis with pitting edema
Other namesRemitting seronegative symmetrical synovitis with pitting oedema[1]
RS3PE
SpecialtyRheumatology

RS3PE typically involves the joints of the extremities, specifically the metacarpophalangeal and proximal interphalangeal joints, wrists, shoulders, elbows, knees and ankles.[4] It is more common in older adults, with the mean age between 70 and 80 years in most studies.[4][5] It occurs more often in men than in women with a 2:1 ratio.[4][6][7] It is unknown how common this condition is.

Signs and symptoms

Individuals affected by RS3PE typically have repeated episodes of inflammation of the lining of their synovial joints and swelling of the end portion of the limbs.[8] The arms and hands are more commonly affected than the legs and feet.[8] Both sides are usually involved though RS3PE can affect only one side in certain cases.[8]

Causes

RS3PE is a constellation of symptoms that can be caused by many other conditions. Since there is no definitive diagnostic test, other conditions have to be ruled out before this rare condition can be diagnosed.

The main differential diagnosis is polymyalgia rheumatica (PMR), although pain, stiffness and weakness at the level of the shoulders and pelvic girdle with associated systemic symptoms (fever, malaise, fatigue, weight loss) is more typical of PMR. Prospective studies have found a subgroup of PMR patients with hand edema, as well as other similarities.[5] Thus, RS3PE has been proposed as a condition related to PMR or even that they are both part of the same disorder.[5] However, PMR typically requires protracted courses of steroids, whereas corticosteroids can be tapered more quickly with persisting remission in RS3PE.[5]

Other rheumatological disorders that can cause the features typical for RS3PE include late onset (seronegative) rheumatoid arthritis, acute sarcoidosis, ankylosing spondylitis and other spondyloarthropathies such as psoriatic arthropathy, mixed connective tissue disease, chondrocalcinosis and arthropathy due to amyloidosis.[6][9]

RS3PE has been documented in patients with cancers (Non-Hodgkin's lymphoma, gastric cancer, pancreatic cancer, lung cancer, breast cancer, colon cancer, prostate cancer and bladder cancer, among others), in whom it might represent a paraneoplastic manifestation.[10][11][12] Other underlying disorders include vasculitides such as polyarteritis nodosa.[8]

Other causes of edema include heart failure, hypoalbuminemia, nephrotic syndrome and venous stasis. The key distinguishing feature is that these conditions don't tend to manifest with pitting edema at the back of the hands.

Pathogenesis

The disease mechanism (pathophysiology) of RS3PE remains unknown. One study suggested a possible role for vascular endothelial growth factor.[13] A study using magnetic resonance imaging found that tenosynovitis of the extensors of the hands and feet is the major contributor to edema.[14]

Diagnosis

Ultrasonography and magnetic resonance imaging of the hands and/or feet have been proposed as useful diagnostic investigations in RS3PE.[15]

Some studies linked RS3PE to HLA-B27 whereas others have not.

Treatment

RS3PE responds excellently to low dose corticosteroids, with sustained and often complete remission. Non-steroidal anti-inflammatory drugs (NSAIDs) have also been used. Hydroxychloroquine has proven effective in some cases.[6]

History

In a 1985 paper published in the Journal of the American Medical Association, McCarty and colleagues first described a case series of patients with this disorder, for which they coined the abbreviation RS3PE.[16] RS3PE was initially thought to represent a form of seronegative rheumatoid arthritis but is now believed to be a separate syndrome.[8]

References
  1. 'Oedema' is the standard form defined in the Concise Oxford English Dictionary (2011), with the precision that the spelling in the United States is 'edema'.
  2. Olivieri I, Salvarani C, Cantini F (2000). "RS3PE syndrome: an overview". Clin. Exp. Rheumatol. 18 (4 Suppl 20): S53–55. PMID 10948764.
  3. Queiro R (March 2004). "RS3PE syndrome: a clinical and immunogenetical study". Rheumatol. Int. 24 (2): 103–05. doi:10.1007/s00296-003-0330-3. PMID 12750942. S2CID 22516577.
  4. Olivé A, del Blanco J, Pons M, Vaquero M, Tena X (February 1997). "The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalán Group for the Study of RS3PE". J. Rheumatol. 24 (2): 333–36. PMID 9034993.
  5. Cantini F, Salvarani C, Olivieri I, et al. (April 1999). "Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study". Ann. Rheum. Dis. 58 (4): 230–36. doi:10.1136/ard.58.4.230. PMC 1752869. PMID 10364902.
  6. Salam A, Henry R, Sheeran T (2008). "Acute onset polyarthritis in older people: Is it RS3PE syndrome?". Cases J. 1 (1): 132. doi:10.1186/1757-1626-1-132. PMC 2543002. PMID 18759976.
  7. Hartley AJ, Manson J, Jawad AS (2010). "Remitting seronegative symmetrical synovitis with pitting oedema". Grand Rounds. 10: 71–73. doi:10.1102/1470-5206.2010.0015 (inactive 31 July 2022). Archived from the original on 2011-07-11. Retrieved 2010-12-20.{{cite journal}}: CS1 maint: DOI inactive as of July 2022 (link)
  8. Kardes S, Karagulle M, Erdogan N (May 2015). "Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) associated with psoriatic arthritis". Scand J Rheumatol. 44 (4): 339–40. doi:10.3109/03009742.2015.1020069. PMID 25958968. S2CID 2298418.
  9. Díez-Porres L, Muñoz-Fernández S, Aguado P, Alonso M, Martín-Mola E (November 2002). "Remitting seronegative symmetrical synovitis with pitting oedema as the first manifestation of psoriatic arthropathy". Rheumatology (Oxford). 41 (11): 1333–35. doi:10.1093/rheumatology/41.11.1333-a. PMID 12422012.
  10. Russell EB (September 2005). "Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia". J. Rheumatol. 32 (9): 1760–61. PMID 16142875. Archived from the original on 2009-04-29. Retrieved 2009-01-29.
  11. Fietta P, Manganelli P (November 2006). "Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia". J. Rheumatol. 33 (11): 2365–66, author reply 2366. PMID 17086622.
  12. Bucaloiu ID, Olenginski TP, Harrington TM (December 2007). "Remitting seronegative symmetrical synovitis with pitting edema syndrome in a rural tertiary care practice: a retrospective analysis". Mayo Clin. Proc. 82 (12): 1510–15. doi:10.4065/82.12.1510. PMID 18053459. Archived from the original on 2007-07-01.
  13. Arima K, Origuchi T, Tamai M, et al. (November 2005). "RS3PE syndrome presenting as vascular endothelial growth factor associated disorder". Ann. Rheum. Dis. 64 (11): 1653–55. doi:10.1136/ard.2004.032995. PMC 1755286. PMID 16227418.
  14. Olivieri I, Salvarani C, Cantini F (February 1997). "Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases?". J. Rheumatol. 24 (2): 249–52. PMID 9034979.
  15. Agarwal V, Dabra AK, Kaur R, Sachdev A, Singh R (September 2005). "Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: ultrasonography as a diagnostic tool". Clin. Rheumatol. 24 (5): 476–79. doi:10.1007/s10067-004-1061-x. PMID 15856369. S2CID 20352825.
  16. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB (November 1985). "Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome". JAMA. 254 (19): 2763–67. doi:10.1001/jama.254.19.2763. PMID 4057484.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.